[go: up one dir, main page]

AU2001230243A1 - Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke - Google Patents

Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke

Info

Publication number
AU2001230243A1
AU2001230243A1 AU2001230243A AU3024301A AU2001230243A1 AU 2001230243 A1 AU2001230243 A1 AU 2001230243A1 AU 2001230243 A AU2001230243 A AU 2001230243A AU 3024301 A AU3024301 A AU 3024301A AU 2001230243 A1 AU2001230243 A1 AU 2001230243A1
Authority
AU
Australia
Prior art keywords
growth factor
stroke
vascular endothelial
preventing
ischemic diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001230243A
Inventor
Peter Carmeliet
Desire Collen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Desire Collen Research Foundation vzw
Original Assignee
FLANDERS INTERUNIVERSITY INST
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002527A external-priority patent/GB0002527D0/en
Application filed by FLANDERS INTERUNIVERSITY INST, Katholieke Universiteit Leuven, Vlaams Instituut voor Biotechnologie VIB filed Critical FLANDERS INTERUNIVERSITY INST
Publication of AU2001230243A1 publication Critical patent/AU2001230243A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pressure Vessels And Lids Thereof (AREA)
  • Dowels (AREA)
  • Clamps And Clips (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Vascular endothelial growth factor, placenta growth factor or combinations of both are useful in the treatment or prevention of stroke or ischemic diseases in mammals.
AU2001230243A 2000-02-04 2001-02-05 Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke Abandoned AU2001230243A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0002527A GB0002527D0 (en) 2000-02-04 2000-02-04 Use of vascular endothelial growth factor (VEGF) placental growth factor (PLGF)or both for the treatment of ischemic and acute myocardial infaction
GB0002527 2000-02-04
US23659400P 2000-09-29 2000-09-29
US60236594 2000-09-29
PCT/EP2001/001208 WO2001056593A2 (en) 2000-02-04 2001-02-05 Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke

Publications (1)

Publication Number Publication Date
AU2001230243A1 true AU2001230243A1 (en) 2001-08-14

Family

ID=26243563

Family Applications (2)

Application Number Title Priority Date Filing Date
AU46435/01A Withdrawn AU4643501A (en) 2000-02-04 2001-02-02 Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
AU2001230243A Abandoned AU2001230243A1 (en) 2000-02-04 2001-02-05 Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU46435/01A Withdrawn AU4643501A (en) 2000-02-04 2001-02-02 Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke

Country Status (9)

Country Link
EP (1) EP1253935B1 (en)
JP (1) JP4969753B2 (en)
AT (1) ATE324905T1 (en)
AU (2) AU4643501A (en)
DE (1) DE60119285T2 (en)
DK (1) DK1253935T3 (en)
ES (1) ES2263582T3 (en)
PT (1) PT1253935E (en)
WO (2) WO2001057181A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759386B2 (en) * 2000-04-06 2004-07-06 Wayne P. Franco Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
ATE378056T1 (en) * 2001-08-10 2007-11-15 Imclone Systems Inc MEDICAL USE OF STEM CELLS EXPRESSING VEGFR-1
ITRM20020119A1 (en) * 2002-03-05 2003-09-05 Geymonat Spa COMPOSITIONS CONTAINING PLGF FOR PHARMACEUTICAL AND COSMETIC USE.
ES2391313T3 (en) 2002-11-16 2012-11-23 Siemens Healthcare Diagnostics Products Gmbh SCD40L, PAPP-A and placental growth factor (PIGF) as a combination of biochemical markers in cardiovascular diseases
EP2295449A1 (en) 2009-09-09 2011-03-16 Dompe PHA.R.MA S.p.A. PLGF-1 in homodimeric form
US10729746B2 (en) * 2013-01-28 2020-08-04 Shire Human Genetic Therapies, Inc. Recombinant placenta growth factor for treating Duchenne muscular dystrophy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
DE69739469D1 (en) * 1996-08-23 2009-07-30 Vegenics Ltd Recombinant vascular endothelial growth factor D (VEGF-D)
EA199900861A1 (en) * 1997-04-25 2000-06-26 Коллатерал Терапьютикс TRACKED PROTEINS, RELATED GROWTH ENDOTHELIUM GROWTH FACTOR
GB2332373A (en) * 1997-12-19 1999-06-23 Merck & Co Inc Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter
JP2002502608A (en) * 1998-02-06 2002-01-29 コラテラル・セラピューティックス・インコーポレイテッド Vessel endothelial cell growth factor, a proangiogenic factor: a variant of VEGF

Also Published As

Publication number Publication date
EP1253935A2 (en) 2002-11-06
DK1253935T3 (en) 2006-09-04
WO2001057181A2 (en) 2001-08-09
DE60119285D1 (en) 2006-06-08
WO2001056593A2 (en) 2001-08-09
EP1253935B1 (en) 2006-05-03
DE60119285T2 (en) 2007-05-10
AU4643501A (en) 2001-08-14
ES2263582T3 (en) 2006-12-16
WO2001056593A3 (en) 2002-04-25
JP2003521522A (en) 2003-07-15
PT1253935E (en) 2006-08-31
JP4969753B2 (en) 2012-07-04
ATE324905T1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
MXPA04001523A (en) Rapamycin dialdehydes.
MXPA04001524A (en) Rapamycin 29-enols.
MY142948A (en) Benzophenones as inhibitors of reverse transcriptase
BG105830A (en) C-21 modified epothilones
WO2000071493A3 (en) INHIBITORS OF FACTOR Xa
MY138285A (en) Fab i inhibitors
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
WO2001015677A3 (en) Use of 5-ht1b/1d agonists to treat otic pain
AU2001230243A1 (en) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
WO2000071716A3 (en) Vascular endothelial growth factor dimers
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
PL345452A1 (en) Chemotaxis-inhibiting protein of staphylococcus
IL131478A0 (en) Methods for treatment of scar tissue
WO2002002121A3 (en) Method for treatment and prevention of mastitis
EP1372648A4 (en) Tie2 receptor kinase inhibitors for treating angiogenic diseases
AU2001265876A1 (en) Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
WO2000048584A3 (en) Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain
DE59805246D1 (en) TISSUE FACTOR INFLUENCING VASOCULAR FORMATION
WO2003070083A3 (en) Endothelial precursor cells for enhancing and restoring vascular function
ZA200110213B (en) The use of the protein UK 114 for inhibiting organ transplant rejection.
UA32315A (en) Technique for skin suturing
GB9723824D0 (en) Cytostatic agents
UA32281A (en) Regenerin composition for treating purulent wounds and trophic ulcers
UA32280A (en) Technique for applying ileocolonic side-to-side anastomosis